FDA’s “Early Communication” On Pancreatitis Risk For Incretin Mimetics Draws Clinician Ire
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency announces that it is evaluating unpublished findings based on pancreatic tissue specimens from a few deceased patients; clinicians say ongoing prospective studies will determine how diabetes drugs affect the pancreas.